These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
683 related articles for article (PubMed ID: 31874110)
1. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499 [TBL] [Abstract][Full Text] [Related]
3. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157 [TBL] [Abstract][Full Text] [Related]
4. Inhibitor of Differentiation-1 Sustains Mutant Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891 [TBL] [Abstract][Full Text] [Related]
5. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer. Feng J; Jiang W; Liu Y; Huang W; Hu K; Li K; Chen J; Ma C; Sun Z; Pang X Biochem Pharmacol; 2020 Jul; 177():113960. PubMed ID: 32298693 [TBL] [Abstract][Full Text] [Related]
6. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol. Albayrak G; Korkmaz FD; Tozcu D; Dogan Turacli I J Cell Biochem; 2019 Jun; 120(6):10564-10571. PubMed ID: 30628735 [TBL] [Abstract][Full Text] [Related]
7. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation. Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157 [TBL] [Abstract][Full Text] [Related]
8. Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-Induced Metabolic and Oxidative Stress. Hong BJ; Park WY; Kim HR; Moon JW; Lee HY; Park JH; Kim SK; Oh Y; Roe JS; Kim MY Cancer Res; 2019 Nov; 79(22):5849-5859. PubMed ID: 31506334 [TBL] [Abstract][Full Text] [Related]
9. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Lim JKM; Delaidelli A; Minaker SW; Zhang HF; Colovic M; Yang H; Negri GL; von Karstedt S; Lockwood WW; Schaffer P; Leprivier G; Sorensen PH Proc Natl Acad Sci U S A; 2019 May; 116(19):9433-9442. PubMed ID: 31000598 [TBL] [Abstract][Full Text] [Related]
10. Wang X; Min S; Liu H; Wu N; Liu X; Wang T; Li W; Shen Y; Wang H; Qian Z; Xu H; Zhao C; Chen Y EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31036704 [TBL] [Abstract][Full Text] [Related]
12. Regulating autophagy facilitated therapeutic efficacy of the sonic Hedgehog pathway inhibition on lung adenocarcinoma through GLI2 suppression and ROS production. Fan J; Zhang X; Wang S; Chen W; Li Y; Zeng X; Wang Y; Luan J; Li L; Wang Z; Sun X; Shen B; Ju D Cell Death Dis; 2019 Aug; 10(9):626. PubMed ID: 31427566 [TBL] [Abstract][Full Text] [Related]
13. Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress. Shimomura I; Watanabe N; Yamamoto T; Kumazaki M; Tada Y; Tatsumi K; Ochiya T; Yamamoto Y JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830081 [TBL] [Abstract][Full Text] [Related]
14. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929 [TBL] [Abstract][Full Text] [Related]
15. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells. Tada M; Sumi T; Tanaka Y; Hirai S; Yamaguchi M; Miyajima M; Niki T; Takahashi H; Watanabe A; Sakuma Y Lung Cancer; 2019 Jul; 133():88-95. PubMed ID: 31200834 [TBL] [Abstract][Full Text] [Related]
16. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma. Huang Z; Chen X; Wang Y; Yuan J; Li J; Hang W; Meng H Front Immunol; 2024; 15():1372215. PubMed ID: 38655266 [TBL] [Abstract][Full Text] [Related]
18. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Roh JL; Kim EH; Jang HJ; Park JY; Shin D Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897 [TBL] [Abstract][Full Text] [Related]
20. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis. Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047 [No Abstract] [Full Text] [Related] [Next] [New Search]